TORONTO, July 25, 2014 /CNW/ - Mr. Eugene Melnyk announced today that he has sold
200,000 common shares of Trimel Pharmaceuticals Corporation (TSX:
TRL) ("Trimel") through the facilities of the Toronto Stock
Exchange, representing approximately 0.12% of the outstanding
shares of Trimel. Following this sale, Mr. Melnyk owns
34,410,783 common shares, representing approximately 21.1% of the
outstanding common shares of Trimel (or 17.9% assuming completion
of Trimel's private placement of 28,801,000 shares announced on
July 17, 2014).
The shares were sold pursuant to the exemption from the
prospectus requirement set out in section 2.8 of National
Instrument 45-102 – Resale of Securities. Mr. Melnyk
filed the associated Form 45-102F1 on SEDAR on July 17, 2014.
Pursuant to the Form 45-102F1, Mr. Melnyk may sell up to an
additional 4,410,783 common shares of Trimel. If Mr. Melnyk
were to dispose of all of these additional shares, he would own
30,000,000 common shares, representing approximately 18.4% of the
outstanding common shares of Trimel (or 15.6% assuming completion
of the aforementioned private placement).
Depending on market conditions and other factors, Mr. Melnyk may
from time to time acquire or dispose of additional securities of
Trimel in the open market, by private agreement or otherwise.
In connection with this news release, an early warning report
will be filed by Mr. Melnyk in accordance with applicable
securities laws. A copy of that early warning report will be
available on SEDAR at www.sedar.com and can be obtained from:
SOURCE Eugene Melnyk